Navigation Links
Organogenesis Receives Two Prestigious Awards for Economic Impact and Manufacturing Excellence
Date:12/1/2008

CANTON, Mass., Dec. 1 /PRNewswire/ -- Organogenesis, Inc., a leading regenerative medicine company, has just been named the recipient of two prestigious awards honoring the company's cutting edge development, manufacturing and economic impact.

Organogenesis' manufacturing division has been named 2008 "Team of the Year" by Pharmaceutical Manufacturing, a prominent industry publication. The "Team of the Year" honor will be highlighted in the magazine's upcoming December 2008 issue. Additionally, the company was honored by the Massachusetts Alliance for Economic Development as the Silver winner of its Fifth Annual Team Massachusetts Economic Impact Award, presented at a November 25th awards event.

Organogenesis was the first company to successfully mass produce living regenerative medicine products -- reaching hundreds of thousands of patients in the U.S. and around the world. Its signature product, Apligraf(R), is the first living cell therapy to have received U.S. Food and Drug Administration (FDA) approvals to close both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).

"We are honored to receive national and state recognition of the company's vision, its ingenuity and hard work," said Geoff MacKay, CEO of Organogenesis. "Organogenesis is committed to bringing the promise of regenerative medicine into everyday medical care. To have our efforts and hard work recognized in this way is very gratifying for the company and our employees."

MacKay continued, "The intricate processes required to mass produce a living cell therapy product require a great deal of innovation and dedication, and our top-notch manufacturing group hits its target every day. This team is in large part responsible for the quality, the growth and the contribution that marks Organogenesis as a regenerative medicine leader in Massachusetts and around the world."

Award Recognizes Manufacturing Excellence

Pharmaceutical Manufacturing, a national trade magazine, is honoring Organogenesis in the small manufacturer category. Pharmaceutical Manufacturing's annual award recognizes manufacturing teams in the life sciences industry that have undertaken sizable challenges, excelled in their work, improved facility morale and team spirit, and achieved measurable, meaningful results. A preview of the "Team of the Year" award article is available online at http://www.pharmamanufacturing.com/articles/2008/161.html.

According to the publication, "The Organogenesis Apligraf Manufacturing Team is responsible for growing Apligraf based upon a proprietary living cell technology with a very short shelf life that requires strict attention to detail and accurate production forecasting. These challenges have defined the manufacturing team. The team has a deep sense of fulfillment from making a meaningful product. Emblematic of its award-winning commitment, the team has firsthand knowledge of how patients benefit, and therefore a unique emotional connection to the product. The team translates this connection into manufacturing excellence."

Award Recognizes Massachusetts Economic Development Contributions

The Fifth Annual Team Massachusetts Economic Impact Award is the only award of its kind in the state, honoring a select group of companies from across the Commonwealth recognized for their outstanding contributions to the Massachusetts economy. Organogenesis is the Silver Medal recipient for 2008.

The Team Massachusetts Economic Impact Awards honor companies in all regions of the state that have expanded the number of jobs in Massachusetts and positively contributed to their surrounding communities. According to the organization, Organogenesis was selected because of its commitment to expanding both its headquarters and life sciences jobs within the state.

The Massachusetts Alliance for Economic Development is a private, non- profit partnership of business, industry leaders, and government dedicated to fostering economic growth in the Commonwealth.

About Regenerative Medicine

A new frontier in healthcare, regenerative medicine utilizes living human cells to repair or replace body tissue damaged by injury, disease or even the natural aging process.

Regenerative medicine is a multidisciplinary field which brings together biology, medicine, and engineering to empower scientists to grow living cells, tissues and organs in the laboratory, and to safely implant them into the human body for the purposes of healing.

About Apligraf(R)

Like human skin, Apligraf contains two layers of living cells: an outer (or epidermal) layer of protective skin cells, and an inner (or dermal) layer of cells. When placed on a wound previously unresponsive to treatment, Apligraf plays an active role by providing cells and proteins that help promote healing. In multiple controlled clinical studies, Apligraf has been shown to be an effective and safe wound care treatment, superior to conventional treatments. It has been used to treat many thousands of patients and is covered extensively by Medicare, Medicaid and by 350 private payers in the U.S.

About Organogenesis, Inc.

Having pioneered the field, Massachusetts based Organogenesis, Inc. is a world leading regenerative medicine company focused in the areas of bio-active wound healing, bio-surgery and oral regeneration. Organogenesis delivers living tissue "on demand," and its mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care.

The company recently established European headquarters located in Switzerland, as well as announced an expansion of its U.S. headquarters. For more information, visit http://www.organogenesis.com.


'/>"/>
SOURCE Organogenesis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Organogenesis Names Regenerative Medicine Expert Dr. Damien Bates Vice President, Medical Affairs
2. Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S.
3. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
4. EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery
5. Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award
6. ECO2 Plastics, Inc. Receives Favorable FDA Opinion Letter Approving the Use of Its Recycled Plastic Flake in Food Packaging Applications
7. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
8. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
9. Accordia Global Health Foundation Receives $12.5 Million Grant From Bill & Melinda Gates Foundation
10. Jon M. Huntsman Receives American Cancer Society Medal of Honor
11. Keryx Biopharmaceuticals Receives Nasdaq Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology: